Free Trial
NASDAQ:NAUT

Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

$2.77
0.00 (0.00%)
(As of 05/22/2024 ET)
Today's Range
$2.75
$2.85
50-Day Range
$2.34
$3.00
52-Week Range
$2.30
$4.65
Volume
49,220 shs
Average Volume
67,088 shs
Market Capitalization
$346.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Nautilus Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
116.6% Upside
$6.00 Price Target
Short Interest
Bearish
1.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$108,316 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.68) to ($0.80) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.04 out of 5 stars

Medical Sector

790th out of 920 stocks

Analytical Instruments Industry

22nd out of 28 stocks

NAUT stock logo

About Nautilus Biotechnology Stock (NASDAQ:NAUT)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

NAUT Stock Price History

NAUT Stock News Headlines

Q1 2024 Nautilus Biotechnology Inc Earnings Call
Nautilus Biotechnology Inc Ordinary Shares NAUT
Q4 2023 Nautilus Biotechnology Inc Earnings Call
Nautilus Biotechnology Inc Ordinary Shares
See More Headlines
Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/30/2024
Today
5/23/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NAUT
Fax
N/A
Employees
167
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+116.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-63,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.99 per share

Miscellaneous

Free Float
74,533,000
Market Cap
$346.97 million
Optionable
Optionable
Beta
1.22
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

NAUT Stock Analysis - Frequently Asked Questions

Should I buy or sell Nautilus Biotechnology stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares.
View NAUT analyst ratings
or view top-rated stocks.

What is Nautilus Biotechnology's stock price target for 2024?

1 analysts have issued 1-year price objectives for Nautilus Biotechnology's shares. Their NAUT share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 116.6% from the stock's current price.
View analysts price targets for NAUT
or view top-rated stocks among Wall Street analysts.

How have NAUT shares performed in 2024?

Nautilus Biotechnology's stock was trading at $2.99 at the beginning of 2024. Since then, NAUT stock has decreased by 7.4% and is now trading at $2.77.
View the best growth stocks for 2024 here
.

When is Nautilus Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our NAUT earnings forecast
.

How were Nautilus Biotechnology's earnings last quarter?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) released its quarterly earnings results on Tuesday, April, 30th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01.

Who are Nautilus Biotechnology's major shareholders?

Nautilus Biotechnology's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.28%), China Universal Asset Management Co. Ltd. (0.02%), SG Americas Securities LLC (0.02%) and Price T Rowe Associates Inc. MD (0.01%). Insiders that own company stock include Anna Mowry, Gwen E Weld, Life Sciences Maste Perceptive, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc, Subramanian Sankar and Sujal M Patel.
View institutional ownership trends
.

How do I buy shares of Nautilus Biotechnology?

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NAUT) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners